The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter prospective study to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial.
 
Masaharu Tada
No Relationships to Disclose
 
Akihiko Ichida
No Relationships to Disclose
 
Junichi Arita
No Relationships to Disclose
 
Etsuro Hatano
Honoraria - Abbvie; Bayer; Chugai Pharma; Eisai; Incyte; Lilly; Merck; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Novartis; Shionogi
Research Funding - Eisai; Tsumura & Co.
 
Susumu Eguchi
No Relationships to Disclose
 
Akio Saiura
No Relationships to Disclose
 
Hiroaki Nagano
No Relationships to Disclose
 
Junichi Shindoh
Honoraria - Eisai
 
Masaji Hashimoto
No Relationships to Disclose
 
Nobuyuki Takemura
No Relationships to Disclose
 
Kojiro Taura
No Relationships to Disclose
 
Yoshihiro Sakamoto
No Relationships to Disclose
 
Yu Takahashi
No Relationships to Disclose
 
Yasuji Seyama
No Relationships to Disclose
 
Yasuharu Sasaki
No Relationships to Disclose
 
Kohei Uemura
No Relationships to Disclose
 
Norihiro Kokudo
No Relationships to Disclose
 
Kiyoshi Hasegawa
Honoraria - Chugai Pharma; Eisai; Taiho Pharmaceutical; Takeda
Research Funding - Fujifilm (Inst); Nipro Corporation (Inst); Shimadzu (Inst)